Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Genomic Health, Inc.    GHDX   US37244C1018

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2015 01/22/2015 01/23/2015 01/26/2015 01/27/2015 Date
31.64(c) 32.48(c) 31.32(c) 32.69(c) 32.39(c) Last
128 507 98 774 83 587 109 687 113 306 Volume
-3.65% +2.65% -3.57% +4.37% -0.92% Change
More quotes
Company
Genomic Health, Inc. is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.The company has a robust pipeline focused on developing tests to optimize the treatment of renal cell cancers, as well as additional treatment decisions in... 
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 279 M
EBIT 2014 -24,5 M
Net income 2014 -25,2 M
Debt 2014 -
Yield 2014 -
Sales 2015 311 M
EBIT 2015 -16,8 M
Net income 2015 -17,0 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 3,72x
Capi. / Sales 2015 3,34x
Capitalization 1 037 M
More Financials
Latest news on GENOMIC HEALTH, INC.
01/14 GENOMIC HEALTH : Assigned Patent
01/05 GENOMIC HEALTH : to Present at the 33rd Annual J.P. Morgan Healthcare Conference
2014 GENOMIC HEALTH : Presents Data from Oncotyle DX Study
2014 GENOMIC HEALTH : Advances Development of Novel Liquid Biopsy-Based Cancer Tests
2014 GENOMIC HEALTH : Claritas Genomics : Appoints Patrick F. Terry as Chief Commerci..
2014 GENOMIC HEALTH : Oncotype DX® DCIS Score™ Represents Breakthrough in Perso..
2014 GENOMIC HEALTH : Announces Presentation of First Prospective Outcomes Study of O..
2014 GENOMIC HEALTH : Advances Development of Novel Liquid Biopsy-Based Cancer Tests
More news
Sector news Biotechnology & Medical Research - NEC
04:01p QIAGEN NV : Introduces QuantiFERON Monitor® for Tracking Immune Function in Soli..
02:37p PUMA BIOTECHNOLOGY : Closes $218 Million Public Offering of Common Stock
08:01a INCYTE : to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF